PARP9 and myelodysplastic syndrome: In comparison to normal controls, the expression levels of SREBF1, MAP3K11, PARP9, and PTPN6 were upregulated, whereas EZH2 and MDM4 were downregulated in the MDS samples (Figure 3A–F).